<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247493</url>
  </required_header>
  <id_info>
    <org_study_id>H-0704-029-205</org_study_id>
    <nct_id>NCT01247493</nct_id>
  </id_info>
  <brief_title>Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)</brief_title>
  <acronym>m-FLAI</acronym>
  <official_title>Multicenter, Phase 2 Clinical Trial Evaluating the Efficacy and Tolerability of Induction and Consolidation Chemotherapy Comprising Fludarabine, Cytarabine, and Attenuated-dose Idarubicin in Elderly Patients With AML(Acute Myeloid Leukemia)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II clinical trial evaluating the efficacy and tolerability of induction and
      consolidation chemotherapy comprising Fludarabine, cytarabine and attenuated-dose Idarubicin
      (modified-FLAI) in the elderly patients with acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate</measure>
    <description>Rate of complete remssion (CR) after two cycles of m-FLAI induction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of serious adverse events (SAE)</measure>
    <description>Number of patients dying from SAE related to m-FLAI induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <description>Event free survival defined as a period from study enrollment to death by from cause or relapse of disease after complete remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <description>Overall survival defined as a period from study enrollment to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive factors for Complete remission</measure>
    <description>Compare complete remission rate according to existence of specific chromosome abnormality and Charlson comorbidity index to evaluate predicative impact of these factors.</description>
  </secondary_outcome>
  <enrollment type="Actual">108</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>induction chemotherapy (fludarabine, cytarabine, idarubicin)</intervention_name>
    <description>fludarabine, cytarabine, idarubicin</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  previously untreated AML (excluding acute promyelocytic leukemia)

          -  age greater than 60 years old

          -  ECOG PS (Eastern Cooperative Oncology Group Performance scale) less than 2

          -  adequate hepatic/ renal/ cardiac function

        Exclusion Criteria:

          -  acute promyelocytic leukemia

          -  significant cardiac disease

          -  combined non-hematologic malignancy

          -  aleukemic leukemia (only granulocytic sarcoma)

          -  CNS (Central Nervous system) involvement

          -  significant comorbidity/ uncontrollable bleeding tendency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inho Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <last_update_submitted>November 23, 2010</last_update_submitted>
  <last_update_submitted_qc>November 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Kim, Inho professor</name_title>
    <organization>SeoulNUH</organization>
  </responsible_party>
  <keyword>fludarabine</keyword>
  <keyword>AML</keyword>
  <keyword>Efficacy</keyword>
  <keyword>tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

